Skip to content

Repligen RGEN Long-Term Debt

Long-Term Debt at other companies

TEC
Bio-TechneTECH
$200M-39.4%
Revvity logo
RevvityRVTY
$3.23B+1.1%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$42.95B+26.4%
Danaher logo
DanaherDHR
$17.56B+9.9%
Agilent Technologies logo
Agilent TechnologiesA
$3.05B-8.9%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$802.9M-33.1%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's long-term debt?
Repligen (RGEN) reported long-term debt of $546.59M in Q1 2026.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.